SuperworthSoligenix SNGX
- Market cap
- $7.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Soligenix's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $130.4K−22% | $244.8K−33% | $117K−55% | $2.3K−99% | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | |
| Cost of revenue | $110.4K−15% | $221.5K+63% | $117K−48% | $2.3K−99% | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | $20K−46% | $23.3K−90% | $0 | $0 | $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $826K−54% | $777.5K−67% | $1.1M+16% | $501.2K−34% | $968.7K+17% | $2.7M+242% | $1.9M+77% | $1.7M+235% | $1.6M+64% | $2.3M−14% | $1.8M−8% | $974.1K−42% |
| SG&A | $973K−27% | $1.4M−4% | $1M−17% | $1.2M+40% | $896.5K−8% | $1.1M−24% | $1.1M+6% | $1.1M−13% | $996.6K+11% | $1.2M+13% | $1.1M+2% | $1.1M+4% |
| −$1.8M−42% | −$2.1M−40% | −$2.1M−2% | −$1.7M+7% | −$1.9M+5% | −$3.7M+74% | −$3M+43% | −$2.8M+58% | −$2.6M+38% | −$3.5M−6% | −$2.9M−5% | −$2.1M−24% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$1.7M−50% | −$2.4M−35% | −$1.9M−13% | −$1.6M+2% | −$1.7M+3% | −$3.4M+40% | −$3.2M+69% | n/a | n/a | n/a | n/a | n/a |
| $0 | −$606.6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$1.7M−50% | −$1.8M−52% | −$1.9M+83% | −$1.6M+2% | −$1.7M+3% | −$3M+64% | −$3M+54% | −$2.7M+64% | −$2.5M+47% | −$2.9M−3% | −$2.8M−4% | −$2M−26% |
| −$2.56−86% | −$2.80−87% | −$2.91−50% | −$1.31−63% | −$0.78−70% | −$1.19−58% | −$0.97−67% | −$0.82−37% | −$0.58−26% | −$0.29−76% | −$0.28−71% | −$0.12−85% | |
| 648.9K+261% | 648.9K+260% | 657.7K+261% | 1.3M+178% | 2.2M+240% | 2.5M+286% | 3M+364% | 3.3M+160% | 4.3M+97% | 10M+300% | 10.2M+233% | 16M+387% |
Gross profit: 4 periods, Q1 FY24 to Q4 FY24: not printed by the filing, worked out from its own lines.
Net income: 25 periods, Q2 FY20 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 15 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 11 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY13 and Q4 FY20: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY14: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x15).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Soligenix's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SNGXSoligenix | $7.9M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Soligenix
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .